000 01519 a2200409 4500
005 20250517185328.0
264 0 _c20181213
008 201812s 0 0 eng d
022 _a1896-494X
024 7 _a10.13075/ijomeh.1896.01037
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aZhang, Hua
245 0 0 _aSubcutaneous administration of infliximab-attenuated silica-induced lung fibrosis.
_h[electronic resource]
260 _bInternational journal of occupational medicine and environmental health
_cJul 2018
300 _a503-515 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAnimals
650 0 4 _aBronchoalveolar Lavage Fluid
_xchemistry
650 0 4 _aI-kappa B Proteins
_xgenetics
650 0 4 _aInfliximab
_xadministration & dosage
650 0 4 _aInjections, Subcutaneous
650 0 4 _aLung
_xpathology
650 0 4 _aMale
650 0 4 _aNF-kappa B
650 0 4 _aNitric Oxide Synthase Type II
_xgenetics
650 0 4 _aPulmonary Fibrosis
_xchemically induced
650 0 4 _aRats, Wistar
650 0 4 _aSignal Transduction
650 0 4 _aSilicon Dioxide
650 0 4 _aSilicosis
_xprevention & control
650 0 4 _aTumor Necrosis Factor-alpha
_xantagonists & inhibitors
700 1 _aSui, Jun-Na
700 1 _aGao, Lei
700 1 _aGuo, Jian
773 0 _tInternational journal of occupational medicine and environmental health
_gvol. 31
_gno. 4
_gp. 503-515
856 4 0 _uhttps://doi.org/10.13075/ijomeh.1896.01037
_zAvailable from publisher's website
999 _c27815354
_d27815354